MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
306.56%
Quick Ratio
306.56%
Cash Ratio
151.81%
Debt to Asset Ratio
31.49%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Marketable securities
    • Prepaid expenses and other curre...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accrued expenses
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
16,991
30,789
47,371
62,786
Marketable securities
14,739
14,614
14,399
14,389
Prepaid expenses and other current assets
2,580
1,540
1,475
1,759
Total current assets
34,310
46,943
63,245
78,934
Property and equipment, net
375
427
480
516
Right-of-use asset - operating lease
659
801
939
1,074
Other assets
392
393
392
405
Total assets
35,736
48,564
65,056
80,929
Accounts payable
1,000
1,535
1,280
1,831
Accrued expenses
9,238
8,755
9,254
8,417
Notes payable
-
96
-
-
Note payable
0
-
379
658
Deferred revenue
234
1,710
1,999
2,141
Operating lease obligation - current portion
720
699
617
597
Total current liabilities
11,192
12,795
13,529
13,644
Deferred revenue - non-current portion
-
0
176
336
Operating lease obligation - non-current portion
63
249
431
610
Total liabilities
11,255
13,044
14,136
14,590
Common stock, 0.001 par value 325,000,000 shares authorized at june30, 2026 and march31, 2026 44,381,433 and 39,624,839 shares issued at june30, 2026 and march31, 2026, respectively
44
40
40
39
Additional paid-in capital
518,759
516,767
515,878
512,398
Treasury stock, at cost, 4,522 shares of common stock held at june30, 2026 and march31, 2026
3,968
3,968
3,968
3,968
Accumulated other comprehensive income
-7
-2
13
14
Accumulated deficit
-490,347
-477,317
-461,043
-442,144
Total stockholders equity
24,481
35,520
50,920
66,339
Total liabilities and stockholders equity
35,736
48,564
65,056
80,929
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$16,991K (-65.31%↓ Y/Y)Marketable securities$14,739K (3.83%↑ Y/Y)Prepaid expenses andother current assets$2,580K (-27.04%↓ Y/Y)Total current assets$34,310K (-48.57%↓ Y/Y)Right-of-use asset -operating lease$659K (-45.36%↓ Y/Y)Other assets$392K (-16.95%↓ Y/Y)Property and equipment,net$375K (-29.25%↓ Y/Y)Total assets$35,736K (-48.15%↓ Y/Y)Total liabilities andstockholders equity$35,736K (-48.15%↓ Y/Y)Total stockholdersequity$24,481K (-56.87%↓ Y/Y)Total liabilities$11,255K (-7.43%↓ Y/Y)Accumulated deficit-$490,347K (-16.00%↓ Y/Y)Treasury stock, at cost,4,522 shares of common...$3,968K (0.00%↑ Y/Y)Accumulated othercomprehensive income-$7K (-800.00%↓ Y/Y)Additional paid-in capital$518,759K (7.31%↑ Y/Y)Total currentliabilities$11,192K (0.33%↑ Y/Y)Operating leaseobligation - non-current...$63K (-91.95%↓ Y/Y)Common stock, 0.001 parvalue 325,000,000...$44K (51.72%↑ Y/Y)Accrued expenses$9,238K (40.35%↑ Y/Y)Accounts payable$1,000K (105.76%↑ Y/Y)Operating leaseobligation - current...$720K (12.50%↑ Y/Y)Deferred revenue$234K (-90.69%↓ Y/Y)

Vistagen Therapeutics, Inc. (VTGN)

Vistagen Therapeutics, Inc. (VTGN)